Crystagen

What is Crystagen?

Crystagen is a synthetic short peptide bioregulator from the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, positioned in the catalog as the thymus / immune-system tissue-targeted entry. Within the Khavinson framework, it is presented as the synthetic chemically-defined counterpart to Thymalin (the natural-extract polypeptide preparation derived from calf thymus) and to Vilon (the dipeptide Lys-Glu) — together comprising the immune-system-focused subset of the bioregulator catalog. Crystagen is most commonly cited as the tripeptide Glu-Asp-Pro (EDP), although the public sequence record is less consistent than for some other Khavinson peptides. Like the rest of the catalog, Crystagen is positioned as a tissue-specific epigenetic regulator that is claimed to selectively interact with thymic tissue to support T-cell maturation, regulate cytokine production, and modulate age-related immune decline. The peer-reviewed footprint specific to Crystagen is among the thinnest in the Khavinson catalog — it is most often discussed in the context of broader Khavinson-peptide reviews rather than in dedicated mechanistic or clinical papers, and the underlying preclinical and clinical work is predominantly Russian-language and not well indexed in major Western databases. Crystagen is sold as a research peptide and as a Russian-market dietary peptide complex (Peptides.ru / Khavinson Peptides line) depending on the channel, and has no FDA approval, no EMA approval, and no formal registration as a Western prescription medicine. It is not a substitute for clinically validated immunomodulators, vaccines, or thymus-replacement therapies.

What Crystagen Is Investigated For

Crystagen is a Khavinson bioregulator topic, not a peptide with a validated Western clinical role. It is one of the thymus-focused entries in the catalog (alongside Thymalin and Vilon) and is positioned as a synthetic chemically-defined short peptide intended to support thymic function and T-cell maturation. The Khavinson group's broader thesis — that short peptides made of one to four amino acids selectively regulate gene expression in tissue-specific ways through direct DNA and chromatin interactions — is the framework within which Crystagen is studied. Within that framework, Crystagen is discussed for age-related thymic involution and the resulting immune senescence, for adjunctive use in chronic infections and immunodeficiency, and as a companion to Thymalin (the natural-extract thymus preparation that pre-dated Crystagen in the catalog) and Vilon (the dipeptide Lys-Glu-NH2 with overlapping immune-system applications). The peer-reviewed footprint specific to Crystagen is unusually thin even by the standards of the Khavinson catalog — there are no PubMed-indexed Crystagen-specific randomized controlled trials, no Western preclinical replication studies, no characterized pharmacokinetics in humans, and no structural validation of the proposed peptide-DNA interaction mechanism specific to Crystagen. The broader Khavinson framework has been described in extensive reviews by Khavinson and his group (Bull Exp Biol Med, Adv Gerontol, IJMS series spanning 1990s-2020s) and by independent reviewers (Morozov 1997, Avolio 2022) but the mechanistic claims — particularly the direct peptide-DNA binding and gene-specific regulation hypotheses — have not been independently validated to the standards of mainstream molecular biology. Consumer-facing marketing that frames Crystagen as a thymus-replacement therapy, an immune-restoration drug, or a treatment for clinically-defined immunodeficiency significantly exceeds what the available evidence can support. The honest framing is that Crystagen is a Russian-tradition short peptide with a real (if mechanistically speculative) basis in Khavinson's bioregulator hypothesis, but it is not a validated Western clinical medicine and should not be treated as such.

History & Discovery

Crystagen emerged from the broader Khavinson 'short peptide bioregulator' research program at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, founded by Vladimir Khavinson and colleagues in the 1970s and 1980s. The program's original focus was on natural-extract polypeptide preparations derived from animal tissues — Thymalin (calf thymus), Epithalamin (pineal gland), Cortexin (cerebral cortex), Prostatilen (prostate), and others — used in Russian clinical practice for age-related and tissue-specific dysfunction. The synthetic chemically-defined short peptide catalog emerged in the 1990s and 2000s as Khavinson and colleagues attempted to identify the active components of the natural-extract preparations and reproduce their effects with synthetic alternatives. The Khavinson framework grew substantially from the late 1990s onward, with the 1997 Morozov International Journal of Immunopharmacology paper (PMID 9637345) representing one of the early peer-reviewed framings of the natural-and-synthetic thymic peptide approach. The 2002 Bull Exp Biol Med paper on thymocyte effects of short peptides (PMID 12420072) included Glu-Asp-Pro (the Crystagen sequence) among the peptides studied for thymocyte signal transduction. The 2012 Bull Exp Biol Med review on epigenetic regulation (PMID 22803113) articulated the broader hypothesis that the catalog peptides function as tissue-specific epigenetic regulators acting through direct DNA and chromatin interactions. The 2022 IJMS paper on POT and LAT transport (PMID 35887081) addressed the question of how short peptides reach intracellular targets, and the 2023 Adv Gerontol paper on KE peptide and SIRT1/PARP regulation (PMID 37782636) extended the framework to specific gene-regulation mechanisms. Within this developing framework, Crystagen was positioned as the synthetic chemically-defined thymus-tissue counterpart to Thymalin and as a companion to Vilon (the dipeptide Lys-Glu). The Russian clinical literature describes Crystagen administration in adults with chronic infections, autoimmune-disease-associated immune dysregulation, and age-related immune decline, with reports of normalized lymphocyte subset proportions, improved cytokine balance, and reduced infection frequency. The Russian Peptides.ru / Khavinson Peptides product line markets Crystagen as a dietary peptide complex. The peer-reviewed footprint specific to Crystagen is among the thinnest in the Khavinson catalog. The 2002 thymocyte paper, the broader Khavinson review papers (which mention Crystagen in the context of the catalog overall), and a small number of Russian-language papers constitute most of the available citation base. There are no PubMed-indexed randomized controlled trials of Crystagen in humans, no Western preclinical replication studies, no characterized human pharmacokinetics, and no structural validation of the proposed Crystagen-specific peptide-DNA interaction mechanism. The broader Khavinson framework has been the subject of substantial peer-reviewed publication and review, but Crystagen-specific work has lagged. Crystagen has no FDA approval, no EMA approval, and no formal registration as a Western prescription medicine. It is sold as a research peptide and as a Russian-market dietary peptide complex. Its place within the Khavinson catalog is well-defined (the thymus / immune-system tissue-specific entry), and its place within Western clinical practice is essentially absent. Anyone considering Crystagen should engage with the broader honest framing — a Russian-tradition short peptide with a real but mechanistically speculative basis in the Khavinson bioregulator hypothesis, not a Western clinical immune-system therapy.

How It Works

Crystagen is a synthetic short peptide developed by a Russian research group (the Khavinson laboratory in St. Petersburg) as part of a broader catalog of 'tissue-specific bioregulators' — small peptides that the Khavinson group claims can selectively turn on or off genes in specific tissues. Crystagen is the thymus / immune-system entry in the catalog, positioned to support T-cell function and counteract age-related decline of the thymus gland. The science underlying this framework is mostly Russian-language, the proposed mechanism (direct peptide-DNA binding) is mechanistically speculative, and there are no Western prescription medicines based on the framework. If you have a real immune-system problem, you should see an immunologist, not buy Crystagen from a peptide vendor.

Crystagen is a synthetic short peptide developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia as part of the broader 'short peptide bioregulator' catalog that includes Epitalon, Cortagen, Pinealon, Cartalax, Livagen, Vesugen, Vilon, Ovagen, Pancragen, Prostamax, Testagen, Thymagen, Bronchogen, Cardiogen, Chonluten, and other tissue-specific entries. Crystagen is most commonly cited as the tripeptide Glu-Asp-Pro (EDP) and is positioned as the thymus / immune-system tissue-targeted member of the catalog. The Khavinson framework proposes that short peptides (one to four amino acids) act as tissue-specific epigenetic regulators that bind directly to DNA, modulate chromatin structure, and selectively regulate gene expression in tissue-specific ways. The hypothesis was articulated in extensive Khavinson-group publications including the 2002 Bull Exp Biol Med paper on thymocyte signaling (PMID 12420072), the 2012 Bull Exp Biol Med review on epigenetic regulation (PMID 22803113), the 2022 IJMS paper on biologically active ultrashort peptide transport (PMID 35887081), and the 2023 Adv Gerontol paper on KE peptide and SIRT1/PARP gene regulation (PMID 37782636). The broader framework has been supported by a range of in vitro experiments showing that Khavinson catalog peptides bind synthetic DNA fragments, modulate gene expression in cultured cells, and produce tissue-typical phenotypic effects in animal models — all of which is interesting biology but has not been validated to the standards of mainstream molecular biology, where claims of direct peptide-DNA binding with sequence-specific gene regulation would require structural-biology characterization (X-ray crystallography or cryo-EM of peptide-DNA complexes) that has not been performed for the Khavinson peptides. Within the framework, Crystagen is positioned as having tissue-selective activity in thymic tissue. The proposed actions include support for T-cell maturation, regulation of cytokine production by thymic stromal cells, and modulation of age-related thymic involution. The effects in the Khavinson framework would be subtle (consistent with epigenetic gene regulation rather than acute pharmacological action), require chronic dosing (typically months in the Khavinson clinical reports), and produce phenotypes interpreted as supportive of healthy immune function in aging populations. The Russian clinical literature describes Crystagen administration in adults with chronic infections, autoimmune-disease-associated immune dysregulation, and age-related immune decline, with reports of normalized lymphocyte subset proportions, improved cytokine balance, and reduced infection frequency — but this dataset has not been independently replicated in Western controlled studies and is largely absent from PubMed. The relationship between Crystagen and other immune-system-focused Khavinson peptides is worth noting. Thymalin is a natural-extract polypeptide preparation from calf thymus, a complex mixture used in Russian clinical practice since the 1970s. Vilon (the dipeptide Lys-Glu) is positioned as a synthetic chemically-defined counterpart to Thymalin and has the most peer-reviewed support among the immune-cluster peptides — Linkova 2023 (IJMS, PMID 37686182), Avolio 2022 (IJMS, PMID 35408963), and others have characterized Vilon-class peptides in monocyte/macrophage and immune-cell contexts. Crystagen sits in the same cluster but with thinner peer-reviewed coverage. Whether Crystagen is mechanistically distinct from Vilon, or whether the two function as tripeptide and dipeptide variants of the same general thymic-bioregulator activity, is not clearly established in the literature. From a Western pharmacological perspective, the principal question is whether short peptides like Crystagen have sufficient in vivo bioavailability, stability, and tissue-targeting to produce the proposed effects. Tripeptides like Glu-Asp-Pro have very short plasma half-lives (typically minutes), poor blood-brain-barrier penetration, and rapid degradation by aminopeptidases, dipeptidyl peptidases, and other peptidases — making the case for tissue-selective gene regulation through direct peptide-DNA binding mechanistically demanding. The Khavinson group has addressed this through proposed transport mechanisms involving POT (proton-coupled oligopeptide transporters) and LAT (large amino acid transporters) characterized in their 2022 IJMS paper (PMID 35887081), but the in vivo concentrations and kinetics required for the proposed gene-regulation effects have not been clearly characterized.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Crystagen:

• 01Whether the proposed mechanism (direct peptide-DNA binding with tissue-specific gene regulation) is correct for Crystagen specifically — not validated to the standards of mainstream molecular biology, with no structural-biology characterization of Crystagen-DNA complexes in the peer-reviewed literature.
• 02Whether the Russian clinical literature on Crystagen replicates in Western controlled trials — no independent replication has been performed.
• 03The pharmacokinetics of Crystagen in humans — administration route, plasma half-life, tissue distribution, and intracellular concentrations all uncharacterized in PubMed-indexed work.
• 04Whether Crystagen has clinical effects distinguishable from those of Vilon (the related dipeptide Lys-Glu) or from those of the natural-extract preparation Thymalin.
• 05The long-term safety profile of chronic Crystagen administration, particularly in subpopulations with autoimmune disease, immunodeficiency, malignancy, or transplantation states.
• 06Whether the broader Khavinson framework will eventually be validated, refined, or supplanted by mainstream molecular biology and pharmacology — a question that applies to the entire bioregulator catalog, not Crystagen specifically.

Forms & Administration

Crystagen is not formulated or approved as a Western prescription therapeutic in any jurisdiction. Within the Russian Khavinson catalog, it is sold as a dietary peptide complex (Peptides.ru / Khavinson Peptides product line) administered orally as capsules or as injectable preparations in some clinical-research settings. Research-grade synthetic Crystagen (Glu-Asp-Pro tripeptide) is sold by some Western peptide reference-standard vendors for laboratory use. There is no FDA-approved formulation, no validated clinical dosing regimen for Western use, and no characterized human pharmacokinetics. Compounded Crystagen from peptide marketplaces has no validated clinical use.

Common Questions

Who Crystagen Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for Crystagen because no Western clinical product has been developed. Theoretical interactions follow from the proposed immune-modulating mechanism. Concurrent use with immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids, biologic disease-modifying antirheumatic drugs) could in theory oppose immunosuppression, with relevance for transplant recipients and patients with autoimmune disease. Concurrent use with immunostimulants or immunomodulators (IVIG, interferons, biologic immunotherapies for cancer) could in theory produce additive effects with unclear clinical implications. Concurrent use with vaccines could in theory alter vaccine responses, although there is no characterized data. Concurrent use with chemotherapy or other cancer treatments could in theory alter immune-system pharmacodynamics, with unclear clinical implications. None of these interactions has been characterized in controlled human studies for Crystagen; they are mechanistic possibilities rather than documented events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions